Myelodysplastic syndromes (MDS)

被引：1

作者：

Burgstaller S. ^{[1
]}

机构：

[1] Abteilung für Innere Medizin IV, Klinikum Wels-Grieskirchen, Grieskirchnerstr. 42, Wels

来源：

memo - Magazine of European Medical Oncology | 2014年 / 7卷 / 3期

关键词：

ASH; 2013; Highlights; Myelodysplastic syndrome;

D O I：

10.1007/s12254-014-0158-4

中图分类号：

学科分类号：

摘要：

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective haematopoiesis and cytopenias in peripheral blood. Transformation into acute myeloid leukaemia is a common complication of MDS. Life expectancy varies between nearly normal and early death. MDS were an important issue at last year's annual meeting of the American Society of Hematology. Like in the years before, the majority of contributions dealt with preclinical aspects. In addition to that, several interesting clinical studies regarding diagnosis and treatment were presented. © 2014 Springer-Verlag Wien.

引用

页码：134 / 137

页数：3

共 23 条

[11]

Fenaux P., Giagounidis A., Sellelag D., A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q, Blood, 118, pp. 3765-3776, (2011)

[12]

List A., Dewald G., Bennet J., Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion, N Engl J Med, 355, pp. 456-465, (2006)

[13]

Komrokji R.S., Al Ali M.H., Pandron E., Et al., A phase II clinical trial of lenalidomide and prednisone in low and intermediate-1 risk, non-del(5q) MDS patients, Blood, (2013)

[14]

Raza A., Tycko B., Lee S., Et al., Oral rigosertib (ON01910.Na) treatment produces an encouraging rate of transfusion independence in lower risk myelodysplastic syndromes (MDS) patients

[15]

A genomic methylation profile is associated with responses, Blood, (2013)

[16]

Valent P., Krieger O., Stauder R., Iron overload in myelodysplastic syndrmes (MDS) - Diagnosis, management, and response criteria: A proposal of the Austrian MDS platform, Eur J Clin Invest, 38, pp. 143-149, (2008)

[17]

Lyons R.M., Marek B.J., Paley C.S., Et al., 48-month update on survival and AML transformation in a 600-patient registry of lower risk MDS patients, Blood, (2013)

[18]

Michallet M., Sobh M., Morisset S., Et al., Significant impact of iron chelation after allogeneic hematopoietic stem cell transplantation on disease recurrence: Potential of anti-leukemic activity, Blood, (2013)

[19]

Kantarjian H.M., Mufti G.J., Fenaux P., Et al., Treatment with romiplostim, a thrombopoietin-receptor agonist, in thrombocytopenic patients with low or intermediate-1 risk myelodysplastic syndrome: Updated follow-up results for acute myeloid leukemia and survival from a randomized, double-blind, placebo-controlled study, Blood, (2013)

[20]

Prica A., Sholzberg M., Buckstein R., Thrombopoietin (TPO)-receptor agonists in myelodysplastic syndromes (MDS): A systematic review and meta-analysis, Blood, (2013)

← 1 2 3 →